Hikma Pharmaceuticals (LON:HIK) Stock Rating Reaffirmed by Berenberg Bank

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “hold” rating reaffirmed by Berenberg Bank in a note issued to investors on Thursday, Marketbeat.com reports. They presently have a GBX 2,000 ($24.70) price target on the stock. Berenberg Bank’s target price points to a potential upside of 4.55% from the stock’s current price.

Separately, Barclays reiterated an “equal weight” rating and set a GBX 2,000 ($24.70) price objective on shares of Hikma Pharmaceuticals in a research note on Monday, April 8th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Hikma Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of GBX 2,068.75 ($25.55).

Hikma Pharmaceuticals Trading Up 3.2 %

HIK stock opened at GBX 1,913 ($23.63) on Thursday. The company has a market capitalization of £4.24 billion, a PE ratio of 2,855.22, a price-to-earnings-growth ratio of 2.38 and a beta of 0.45. The company has a debt-to-equity ratio of 53.92, a quick ratio of 1.27 and a current ratio of 1.57. Hikma Pharmaceuticals has a 52 week low of GBX 1,711 ($21.13) and a 52 week high of GBX 2,222 ($27.45). The company’s 50-day simple moving average is GBX 1,887.50 and its 200 day simple moving average is GBX 1,870.12.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.